Industries > Pharma > Global Vaccines Sales Market Forecast 2019-2029

Global Vaccines Sales Market Forecast 2019-2029

Paediatric Vaccines, Adult Vaccines, Elderly Vaccines, Travel Vaccines, Therapeutic Vaccines, Prevnar, Gardasil, Fluzone, Pentacel, ProQuad, Infanrix/Pediarix, Zostavax, RotaTeq, Menactra

PUBLISHED: 25 June 2019
PAGES: 201
PRODUCT CODE: PHA0453

Clear
WOOCS 2.2.1

The global vaccines market is estimated at $41bn in 2018 and is expected to grow at a CAGR of 10.9% during the forecast period. The Paediatric Vaccines segment held 56% of the Global Vaccines market in 2018.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 201-page report you will receive 121 charts– all unavailable elsewhere.

The 201-page report provides clear detailed insight into the global vaccines sales market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Vaccines Sales Market forecasts from 2019-2029

• Global Vaccines Sales Market forecasts from 2019-2029 by Submarket:
• Paediatric Vaccines
• Adult Vaccines
• Elderly Vaccines
• Travel Vaccines
• Therapeutic Vaccines

Global Vaccines Sales Market Forecast 2019-2029

• Global Vaccines Sales Market forecasts from 2019-2029 by Leading Vaccines:
• Prevnar
• Gardasil
• Fluzone
• Pentacel
• ProQuad
• Infanrix/Pediarix
• Zostavax
• RotaTeq
• Hepatitis Vaccines
• Menactra

• Global Vaccines Sales Market forecasts from 2019-2029 by Regional and National Market:
• US
• EU5: Germany, France, Italy, UK, Spain
• Japan
• Brazil
• Russia
• India
• China

• Profiles of the selected leading companies:
• AstraZeneca
• Eli Lilly
• Emergent BioSolutions Inc.
• GlaxoSmithKline
• Johnson & Johnson
• Merck & Co.
• Pfizer
• Sanofi
• Serum Indian Institute Pvt. Ltd.
• Takeda

• The Vaccines Market Pipeline Analysis

• A SWOT and STEP analysis of the global vaccines market

• Key Questions Answered by this Report:
• What is the current size of the overall global human vaccines market? How much will this market be worth from 2018 to 2029?
• What are the main drivers and restraints that will shape the overall vaccines market over the next ten years?
• What are the main segments within the overall human vaccines market? How much will each of these segments be worth for the period 2018 to 2029? How will the composition of the market change during that time, and why?
• What factors will affect that industry and market over the next ten years?
• What are the largest national markets for the world vaccines? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2028?
• How will political and regulatory forces influence regional markets?
• How will market shares of the leading national markets change by 2029, and which geographical region will lead the market in 2029?
• Who are the leading companies and what are their activities, results, developments and prospects?
• What are the leading vaccines? What are their revenues and latest developments?
• What are some of the most prominent human vaccines currently in development?
• What are the main trends that will affect the world vaccines market between 2018 and 2029?
• What are the main strengths, weaknesses, opportunities and threats for the market?
• What are the social, technological, economic and political influences that will shape that industry over the next ten years?
• How will the global vaccines market evolve over the forecasted period, 2018 to 2029?
• How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2018 to 2029?
• Which therapies can succeed and what revenues could they generate to 2029?
• What will be the main commercial drivers for the market from 2018 to 2029?
• How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth?
• How will that industry evolve between 2018 and 2029, especially in R&D?

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Vaccines Sales Market. You find data, trends and predictions.

Buy our report today Global Vaccines Sales Market Analysis : Paediatric Vaccines, Adult Vaccines, Elderly Vaccines, Travel Vaccines, Therapeutic Vaccines, Prevnar, Gardasil, Fluzone, Pentacel, ProQuad, Infanrix/Pediarix, Zostavax, RotaTeq, Menactra.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Global Vaccines Sales Market Forecast 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Vaccines Sales Market Forecast 2019-2029


Latest Pharma news

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

READ

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

READ

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

READ

Categories

Category